CAS: 129083-44-9; 1,1'-(4,4'-(Disulfanediylbis(Methylene))Bis(Thiazole-4,2-Diyl))Diguanidine (Famotidine Impurity)

该化合物是与广泛使用的H2-受体对立体异丙胺(H2-受体异丙胺)相关的一种关键杂质.该化合物的结构特征是两个2-guanidino-4-thiazolyl组别之间的脱硫联系,因此在药品质量控制中与分析和监管有关.纯度超过85%,它作为杂质特征分析,方法验证和稳定性研究的可靠参考标准.其定义明确的化学特性确保按照药用准则准确识别和量化.这种杂质对于通过协助在制造和储存过程中发现和控制潜在的污染物来确保芳虫制剂的安全和有效性至关重要.

英文名称1,1'-(4,4'-(Disulfanediylbis(Methylene))Bis(Thiazole-4,2-Diyl))Diguanidine (Famotidine Impurity)
中文名称1,1'-(4,4'-(二硫烷二基双(亚甲基))双(噻唑-4,2-二基))二胍 (法莫替丁杂质)
IUPAC名称1,1'-(disulfanediylbis(1-methylene-1H-1l4-thiazole-4,2-diyl))diguanidine
其它别名N,N'''-[亚二硫基二(亚甲基-4,2-噻唑二基)]二胍; Famotidine Disulfide
CAS编号129083-44-9
MFCD编号:MFCD18382185
EINECS号:641-496-4
FDA UNII编号:RW4R9WD6HN
分子式:C10H14N8S4分子量:374.55
产品CID: 452464
产品分类有机原料→分子砌块→芳杂环类化合物→噻唑类化合物

相似结构搜索
InChIKey: ZWHJVLVEEDAPHN-UHFFFAOYSA-N
InChI=1S/C10H14N8S4/c1-21-3-5(15-9(21)17-7(11)12)19-20-6-4-22(2)10(16-6)18-8(13)14/h3-4H,1-2H2,(H4,11,12,15,17)(H4,13,14,16,18)
计算化学: 氢键受体数8.0氢键供体数6.0可旋转键数7.0

相似化合物

106649-96-1 124646-10-2 88046-01-9

物理性质

熔点155-157 °C
沸点601.0±65.0 °C(预测)
密度1.86±0.1 g/cm3
PSA:149.58
LogP:2.29194
溶解性DMF(微溶),甲醇(微溶,超声处理)
外观形态固体-粉末
储存条件Hygroscopic, -20 °C Freezer, Under Inert Atmosphere
产品应用该化合物是抑制胃酸生产的一种甲胺H2-受体对立剂,通常用于治疗胃溃疡疾病和胃透析性回流疾病.

MSDS等安全信息

警示词Warning
危险描述H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
防范说明P264, P270, P301+P317, P330, and P501
UN编号NONH for all modes of transport
WGK Germany3

合成工艺路线路线简述

76824-35-6 + 100-52-7 = 129083-44-9 + 106433-44-7 + 1994267-84-3 + 90237-03-9 + 76824-16-3 + 89268-62-2 + 124646-10-2 + 107880-74-0
反应条件:1.1 Solvents: Water; 4 H,80 °C
标题:Identification,Synthesis,And Characterization Of Unknown Impurity In The Famotidine Powder For Oral Suspension Due To Excipient Interaction By Uplc-Ms/ms And Nmr
作者:Hotha,Kishore Kumar; Patel,Tejashkumar; Roychowdhury,Swapan; Subramanian,Veerappan
参考文献:Journal Of Liquid Chromatography & Related Technologies 日期:2015 卷标:38(9) 页码:977-985

专利信息

专利号:US-2016376245-A1
优先权日:2015-06-23
标题 :Impurity of famotidine
发明人：HOTHA KISHORE KUMAR
权利人:GAVIS PHARMACEUTICALS
摘要:The present invention is directed to a new impurity of famotidine, process for preparing and isolating it. The invention is further related to analytical methods of its identification, synthesis and characterization.

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献

1: Lin SY. An overview of famotidine polymorphs: solid-state characteristics, thermodynamics, polymorphic transformation and quality control. Pharm Res. 2014 Jul;31(7):1619-31. doi: 10.1007/s11095-014-1323-5. Epub 2014 Mar 1. Review. doi: 10.1007/s40261-013-0113-x. Review. 6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Expert Rev Gastroenterol Hepatol. 2012 Feb;6(1):25-35. doi: 10.1586/egh.11.88. Review. Review. Review.

合成参考文献

参考文献:10.1365/s10337-004-0386-6
摘要:Helali N, Darghouth F, Monser L. RP-HPLC Determination of Famotidine and its Potential Impurities in Pharmaceuticals. Chromatographia. 2004 Aug 18;60(7-8):455–60. doi: 10.1365/s10337-004-0386-6.